See more : Aeso Holding Limited (8341.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Nanobiotix S.A. (NBTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Nanobiotix S.A., a leading company in the Biotechnology industry within the Healthcare sector.
- UWC Berhad (5292.KL) Income Statement Analysis – Financial Results
- China Healthwise Holdings Limited (0348.HK) Income Statement Analysis – Financial Results
- GI Innovation, Inc. (358570.KQ) Income Statement Analysis – Financial Results
- Andretti Acquisition Corp. (WNNR-UN) Income Statement Analysis – Financial Results
- NCC Bluewater Products Limited (NCCBLUE.BO) Income Statement Analysis – Financial Results
Nanobiotix S.A. (NBTX)
About Nanobiotix S.A.
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 30.06M | 4.78M | 10.00K | 50.00K | 68.00K | 116.00K | 251.97K | 1.56M | 265.54K | 967.50K | 184.94K | 74.15K | 1.36M |
| Cost of Revenue | 0.00 | 985.00K | 0.00 | 0.00 | 0.00 | 0.00 | 345.59K | 436.31K | 359.61K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 30.06M | 3.79M | 10.00K | 50.00K | 68.00K | 116.00K | -93.62K | 1.12M | -94.07K | 967.50K | 184.94K | 74.15K | 1.36M |
| Gross Profit Ratio | 100.00% | 79.38% | 100.00% | 100.00% | 100.00% | 100.00% | -37.16% | 72.00% | -35.42% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 38.40M | 32.64M | 30.38M | 24.33M | 30.41M | 20.89M | 16.34M | 16.92M | 13.90M | 8.08M | 6.03M | 4.31M | 5.21M |
| General & Administrative | 21.66M | 17.48M | 19.43M | 14.27M | 18.64M | 12.62M | 12.34M | 10.26M | 7.19M | 4.30M | 3.61M | 1.81M | 1.30M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 21.66M | 17.48M | 19.43M | 14.27M | 18.64M | 12.62M | 12.34M | 10.26M | 7.19M | 4.30M | 3.61M | 1.81M | 1.30M |
| Other Expenses | -3.22M | -3.41M | -2.64M | -2.07M | -2.20M | -3.33M | -337.89K | 160.23K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 56.84M | 46.70M | 47.18M | 36.53M | 46.85M | 30.18M | 25.52M | 23.41M | 17.41M | 10.59M | 8.36M | 5.23M | 5.23M |
| Cost & Expenses | 56.84M | 46.70M | 47.18M | 36.53M | 46.85M | 30.18M | 25.52M | 23.41M | 17.41M | 10.59M | 8.36M | 5.23M | 5.23M |
| Interest Income | 1.22M | 256.00K | 6.17M | 4.68M | 105.00K | 34.00K | 33.03K | 59.49K | 183.22K | 196.65K | 59.06K | 46.00 | 11.53K |
| Interest Expense | 7.98M | 5.84M | 590.00K | 333.00K | 4.79M | 847.00K | 108.37K | 102.20K | 59.52K | 55.73K | 24.57K | 77.01K | 30.77K |
| Depreciation & Amortization | 1.51M | 1.50M | 1.56M | 1.76M | 1.77M | 569.00K | 345.59K | 436.31K | 456.08K | 307.56K | 233.93K | 146.53K | 197.62K |
| EBITDA | -30.09M | -45.15M | -45.61M | -31.49M | -44.78M | -29.33M | -25.55M | -21.21M | -16.49M | -9.11M | -7.89M | -5.01M | -5.02M |
| EBITDA Ratio | -100.09% | -1,084.63% | -409,950.00% | -59,906.00% | -65,845.59% | -25,282.76% | -10,172.33% | -1,360.96% | -6,208.97% | -942.01% | -4,264.36% | -6,781.21% | -368.90% |
| Operating Income | -26.78M | -46.70M | -52.58M | -36.43M | -46.78M | -30.07M | -25.27M | -21.85M | -17.14M | -9.62M | -8.18M | -5.15M | -5.23M |
| Operating Income Ratio | -89.09% | -977.85% | -525,790.00% | -72,856.00% | -68,792.65% | -25,919.83% | -10,027.88% | -1,402.65% | -6,455.32% | -994.29% | -4,422.79% | -6,948.91% | -384.27% |
| Total Other Income/Expenses | -12.80M | -10.33M | 5.58M | 2.85M | -4.13M | -278.00K | -876.00K | 64.61K | 138.56K | 142.52K | 34.50K | -99.18K | -19.34K |
| Income Before Tax | -39.58M | -57.03M | -47.00M | -33.61M | -50.91M | -30.35M | -26.14M | -21.79M | -17.00M | -9.48M | -8.14M | -5.25M | -5.25M |
| Income Before Tax Ratio | -131.68% | -1,194.16% | -469,990.00% | -67,228.00% | -74,870.59% | -26,159.48% | -10,375.61% | -1,398.50% | -6,403.14% | -979.56% | -4,404.14% | -7,082.66% | -385.69% |
| Income Tax Expense | 120.00K | 10.00K | 5.00K | 9.00K | 3.00K | -449.00K | 20.00 | 90.43K | 37.58K | 79.27K | 22.91K | 78.89K | 30.67K |
| Net Income | -39.70M | -57.04M | -47.00M | -33.62M | -50.92M | -29.90M | -26.14M | -21.88M | -17.00M | -9.56M | -8.14M | -5.33M | -5.25M |
| Net Income Ratio | -132.08% | -1,194.37% | -470,040.00% | -67,246.00% | -74,875.00% | -25,772.41% | -10,375.62% | -1,404.31% | -6,403.14% | -987.75% | -4,404.14% | -7,189.05% | -385.69% |
| EPS | -1.08 | -1.64 | -1.35 | -1.38 | -2.35 | -1.52 | -1.50 | -1.43 | -1.20 | -0.74 | -0.76 | -0.65 | -3.42 |
| EPS Diluted | -1.08 | -1.64 | -1.35 | -1.38 | -2.35 | -1.52 | -1.50 | -1.43 | -1.20 | -0.74 | -0.76 | -0.65 | -3.42 |
| Weighted Avg Shares Out | 36.93M | 34.85M | 34.73M | 24.39M | 21.63M | 19.62M | 17.43M | 15.28M | 14.14M | 12.87M | 10.75M | 8.22M | 1.54M |
| Weighted Avg Shares Out (Dil) | 36.93M | 34.85M | 34.73M | 24.39M | 21.63M | 19.63M | 17.48M | 15.28M | 14.14M | 12.87M | 10.75M | 8.22M | 1.54M |
Nanobiotix Announces Positive First Results for Novel NBTXR3 in Rectal Cancer Study at ASCO-GI 2021
Nanobiotix Announces Revenue for Second Quarter 2020 and First Half Year 2020
Source: https://incomestatements.info
Category: Stock Reports